Medicare and cost-effectiveness analysis

New England Journal of Medicine

Volumn 353, Issue 14, 2005, Pages 1516-1522

  Neumann, Peter J ^a   Rosen, Allison B ^b,c   Weinstein, Milton C ^a  

^a HARVARD CENTER FOR RISK ANALYSIS   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ALZHEIMER DISEASE; ARTICLE; COST EFFECTIVENESS ANALYSIS; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; MEDICAID; MEDICAL DECISION MAKING; MEDICARE; OUTCOMES RESEARCH; PRIORITY JOURNAL; REIMBURSEMENT;

HEALTH CARE AND PUBLIC HEALTH;

COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE RATIONING; HEALTH EXPENDITURES; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MEDICARE; REIMBURSEMENT MECHANISMS; RISK SHARING, FINANCIAL; TECHNOLOGY ASSESSMENT, BIOMEDICAL; THERAPEUTIC EQUIVALENCY; UNITED STATES;

EID: 25844477670     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsb050564     Document Type: Article

References (65)

1. Neumann PJ. Using cost-effectiveness analysis to improve health care: opportunities and barriers. New York: Oxford University Press, 2005.
2. Tunis SR. Why Medicare has not established criteria for coverage decisions. N Engl J Med 2004;350:2196-8.
3. Medicare program: criteria and procedures for making medical services coverage decisions that relate to health care technology. Fed Regist 1989;54(30):4302-18.
4. Foote SB. Why Medicare cannot promulgate a national coverage rule: a case of regula mortis. J Health Polit Policy Law 2002;27:707-30.
5. Kim M, Blendon RJ, Benson JM. How interested are Americans in new medical technologies? A multicountry comparison. Health Aff (Millwood) 2001;20(5):194-201.
6. Garber AM. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff (Millwood) 2004;Suppl Web Exclusives:W4284-W4296.
7. Neumann PJ. Why don't Americans use cost-effectiveness analysis? Am J Manag Care 2004;10:308-12.
8. Tunis SR. Economic analysis in health care decisions. Am J Manag Care 2004;10:301-4.
9. Newhouse JP. Financing Medicare in the next administration. N Engl J Med 2004;351:1714-6.
10. Gillick MR. Medicare coverage for technological innovations - time for new criteria? N Engl J Med 2004;350:2199-203.
11. McClellan MB, Tunis SR. Medicare coverage of ICDs. N Engl J Med 2005;352:222-4.
12. Atlas RF. The role of PBMs in implementing the Medicare prescription drug benefit. Health Aff (Millwood) 2004;23:Suppl Web Exclusives:W4504-W4515.
13. Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff (Millwood) 2004;23(1):124-34.
14. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624-32.
15. FDC reports: AHRQ drug effectiveness comparisons will focus on 10 "priority conditions." The Pink Sheet. December 20, 2004;66(51):11.
16. Danzon PM, Wilensky GR, Means KE. Alternative strategies for Medicare payment of outpatient prescription drugs - Part B and beyond. Am J Manag Care 2005;11:173-80.
17. Kassirer JP, Angell M. The Journal's policy on cost-effectiveness analyses. N Engl J Med 1994;331:669-70.
18. Evans RG. Manufacturing consensus, marketing truth: guidelines for economic evaluation. Ann Intern Med 1995;123:59-60.
19. Rennie D, Luft HS. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA 2000;283:2158-60.
20. Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. Growth and quality of the cost-utility literature, 1976-2001. Value Health 2005;8:3-9.
21. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172-7.
22. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-8.
23. Taylor RS, Drummond MF, Salkeld G, Sullivan SD. Inclusion of cost-effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 2004;329:972-5.
24. Coffield AB, Maciosek MV, McGinnis JM, et al. Priorities among recommended clinical preventive services. Am J Prev Med 2001;21:1-9.
25. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-84.
26. National Health Interview Survey (NHIS) 2000, 2001. (Accessed September 15, 2005, at http://www.cdc.gov/nchs/nhis.htm.)
27. Behavioral Risk Factor Surveillance System. (Accessed September 15, 2005, at http://apps.nccd.cdc.gov/brfss/.)
28. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. JAMA 2003;289:305-12. [Erratum, JAMA 2003;289:2649.]
29. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278:1333-9. [Erratum, JAMA 2000;283:341.]
30. Phillips KA, Shlipak MG, Coxson P, et al. Health and economic benefits of increased beta-blocker use following myocardial infarction. JAMA 2000;284:2748-54.
31. Neumann PJ, Levin BS. Do HEDIS measures reflect cost-effective practices? Am J Prev Med 2002;23:276-89.
32. Greene J, Blustein J, Laflamme KA. Use of preventive care services, beneficiary characteristics, and Medicare HMO performance. Health Care Financ Rev 2001;22:141-53.
33. The Health Plan Employer Data and Information Set (HEDIS). (Accessed September 15, 2005, at http://www.ncqa.org/Programs/HEDIS.)
34. US Preventive Services Task Force. Osteoporosis screening. (Accessed September 15, 2005, at http://www.ahrq.gov/clinic/3rduspstf/osteoporosis/.)
35. Adler GS, Shatto A. Screening for osteoporosis and colon cancer under Medicare. Health Care Financ Rev 2002;23:189-200.
36. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145-51.
37. Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000;132:780-7. [Erratum, Ann Intern Med 2002;136:635.]
38. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001;103:38-44.
39. Lynd LD, O'Brien BJ. Cost-effectiveness of the implantable cardioverter defibrillator: a review of the current evidence. J Cardiovasc Electrophysiol 2003;14:Suppl 9:S99-S103.
40. Jauhar S, Slotwiner DJ. The economics of ICDs. N Engl J Med 2004;351:2542-4.
41. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353:1471-80.
42. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of endstage renal disease treatment. Med Decis Making 2002;22:417-30.
43. Medicare dialysis facilities: beneficiary access stable and problems in payment system being addressed. Washington, D.C.: General Accounting Office, 2004. (Report no. GAO-04-450.)
44. Ramsey SD, Berry K, Etzioni R, et al. Cost-effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med 2003;348:2092-102.
45. Samson D. Special Report: cost-effectiveness of left ventricular assist devices as destination therapy for end-stage heart failure. TEC Assessments 2005;19(2):1-36.
46. McMahon PM, Araki SS, Sandberg EA, Neumann PJ, Gazelle GS. The cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology 2003;228:515-22.
47. Knopman DS, Petersen RC, Edland SD, Cha RH, Rocca WA. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994. Neurology 2004;62:506-8.
48. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology 2002;58:1615-21.
49. Stanton MS. Implantable cardioverter defibrillators: an excellent case study. Health Aff (Millwood) 2005;24(1):52-4.
50. Rawlins MD, Culyer AJ. National Institute of Clinical Excellence and its value judgments. BMJ 2004;329:224-7.
51. Blendon RJ, Benson JM, Brodie M, et al. Voters and health care in the 1996 election. JAMA 1997;277:1253-8.
52. Robinson JC. The end of managed care. JAMA 2001;285:2622-8.
53. Daniels N, Sabin JE. Setting limits fairly: can we learn to share medical resources? New York: Oxford University Press, 2002.
54. Neumann PJ, Divi N, Beinfeld MT, et al. Medicare's national coverage decisions, 1999-2003: quality of evidence and review times. Health Aff (Millwood) 2005;24(1):243-54.
55. Kolata G. Medicare covering new treatments but with a catch. New York Times. November 5, 2004:A1.
56. Chapman S, Reeve E, Rajaratnam G, Neary R. Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care. BMJ 2003;326:707-9.
57. Lipman T. The failings of NICE: NICE and evidence based medicine are not really compatible. BMJ 2001;322:489-90.
58. Smith R. The failings of NICE: time to start work on version 2. BMJ 2000;321:1363-4.
59. Dent THS, Sadler M. From guidance to practice: why NICE is not enough. BMJ 2002;324:842-5.
60. Walker R. The failings of NICE: "spinning" is not NICE. BMJ 2001;322:490.
61. Rawlins MD. NICE work - providing guidance to the British National Health Services. N Engl J Med 2004;351:1383-5.
62. PausJenssen AM, Singer PA, Detsky AS. Ontario's formulary committee: how recommendations are made. Pharmacoeconomics 2003;21:285-94.
63. Mitchell AS. Antipodean assessment: activities, actions, and achievements. Int J Technol Assess Health Care 2002;18:203-12.
64. Reinhardt UE. An information infrastructure for the pharmaceutical market. Health Aff (Millwood) 2004;23(1):107-12.
65. Consumer Reports launches public education campaign to help consumers save on medicines. New York: Consumers Union, December 9, 2004.